Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ECLIPSE: ASP-1929 photoimmunotherapy + pembrolizumab vs standard of care in first-line recurrent HNSCC
jRCT2061250025Phase 3Recruiting
- Sponsor
- Rakuten Medical, Inc.
- Start
- Jun 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, open-label trial in head and neck squamous cell carcinoma (HNSCC) comparing ASP-1929 photoimmunotherapy + pembrolizumab with Physician’s choice standard of care (2 arms). Primary endpoint: Overall survival. Started Jun 2025; status: recruiting.
02
Drugs
cetuximab sarotalocan sodiumpembrolizumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on jRCT2061250025.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2061250025.